9月3日，默克將在上海辦公室舉辦首屆開放創(chuàng)新日(Open Innovation Day)，與合作伙伴共同探索創(chuàng)新治療藥物，以滿足我們專注治療領(lǐng)域中未被滿足的臨床需求。

我們誠邀創(chuàng)新者向默克醫(yī)藥健康全球領(lǐng)導(dǎo)者展示其開創(chuàng)性的科學(xué)成果，與行業(yè)領(lǐng)袖交流并深入了解治療前沿。活動將以閉門形式進行。

我們關(guān)注的方向

在以下領(lǐng)域的創(chuàng)新資產(chǎn)、模式和技術(shù)：

• 心血管、代謝與內(nèi)分泌

• 生殖

• 神經(jīng)學(xué)

• 腫瘤學(xué)（重點關(guān)注實體瘤）

• 以人工智能（AI）和機器學(xué)習(xí)（ML）為核心，旨在提升藥物發(fā)現(xiàn)與開發(fā)的方案。

此外，我們尋求在構(gòu)思、原型設(shè)計、試點和商業(yè)推廣各階段具有實質(zhì)性創(chuàng)新的項目，這些項目應(yīng)符合默克關(guān)注的重點領(lǐng)域，并具備清晰的商業(yè)化路徑。我們鼓勵建立在切實可行、可擴展的解決方案基礎(chǔ)上的早期創(chuàng)新。本次活動不設(shè)現(xiàn)金獎勵。

我們的評估標(biāo)準(zhǔn)

模式和技術(shù)的創(chuàng)新性

· 在療效、安全性、給藥途徑等方面顯著優(yōu)于現(xiàn)有標(biāo)準(zhǔn)療法和在研資產(chǎn)，為患者提供更優(yōu)治療獲益。

· 創(chuàng)新性需有扎實數(shù)據(jù)，或臨床試驗結(jié)果支持。

治療領(lǐng)域的相關(guān)性

· 與默克的重點關(guān)注領(lǐng)域保持一致，包括心血管、代謝與內(nèi)分泌、生殖、神經(jīng)學(xué)、腫瘤學(xué)（重點關(guān)注實體瘤）和相關(guān)技術(shù)平臺。

臨床驗證水平

· 心血管、代謝與內(nèi)分泌和生殖領(lǐng)域：希望具有臨床概念驗證（PoC），我們將優(yōu)先考慮處于III期及以后的資產(chǎn)。

· 神經(jīng)學(xué)和腫瘤：我們對各個階段的資產(chǎn)持開放態(tài)度，強有力的PoC將是加分項。

· 技術(shù)平臺：我們傾向于已有臨床應(yīng)用的案例。

推介方案的完整性

我們希望提案中包含以下內(nèi)容：

公司簡介

· 歷史、業(yè)務(wù)重點、地理位置、規(guī)模、財務(wù)狀況及管理團隊信息。

技術(shù)和產(chǎn)品管線

· 核心技術(shù)平臺的科學(xué)原理及應(yīng)用詳細描述。

· 管線概覽，包括項目名稱、作用機理（MoA）、適應(yīng)癥、開發(fā)階段以及權(quán)利持有者或合作伙伴信息。

資產(chǎn)詳情

· 疾病背景：流行病學(xué)數(shù)據(jù)、當(dāng)前標(biāo)準(zhǔn)護理、未滿足的需求及市場潛力；

· 作用機理（MoA）與靶點理論；

· 差異化策略及支持數(shù)據(jù)；

· 目標(biāo)產(chǎn)品概況（TPP），尤其針對后期產(chǎn)品。

· 競爭格局：與標(biāo)準(zhǔn)護理和新興競爭者的簡要對比（涵蓋作用機理、給藥途徑、目標(biāo)患者人群、治療方案，以及臨床前和臨床數(shù)據(jù)的療效與安全性對比）。

· 臨床開發(fā)計劃及注冊路線：已完成、正在進行及計劃中的試驗，關(guān)鍵的監(jiān)管里程碑（請采用甘特圖展示的時間表）。

· 代表性結(jié)果：研究設(shè)計、數(shù)據(jù)及結(jié)論，并提供交叉試驗比較的數(shù)據(jù)來源引用。

· 與藥品監(jiān)管機構(gòu)的溝通結(jié)果。

· CMC及材料供應(yīng)情況，尤其針對后期資產(chǎn)和先進技術(shù)領(lǐng)域。

· 知識產(chǎn)權(quán)信息：包含任何上游義務(wù)。

· 合作潛力及雙方的戰(zhàn)略契合度。

· 首選合作模式及期望，例如對未來臨床試驗的投資及保留的權(quán)利。

· 聯(lián)系方式。

為符合保密要求

包括主要亮點的基礎(chǔ)上可以簡要陳述

團隊的資質(zhì)和能力

請重點強調(diào)團隊的能力

申請安排與方式

申請?zhí)峤粫r間：7月至8月初

為確保流程迅速響應(yīng)，申請將采取“滾動評審制”

符合條件的申請者將獲邀進行展示

請將包含非保密信息的推介方案及

相關(guān)支持文件發(fā)送至：grace.xiao@merckgroup.com

我們鼓勵所有致力于推動行業(yè)進步的創(chuàng)新者的積極申請，把握這一在該領(lǐng)域產(chǎn)生深遠影響的機會，共同推動醫(yī)藥健康領(lǐng)域的創(chuàng)新與合作！

Merck is excited to announce the Merck Open Innovation Day in China, aimed at identifying the next generation of therapeutics that address the unmet needs in our focused therapeutic areas. This event invites innovators to showcase their groundbreaking science to Merck Healthcare leaders in a unique closed-door presentation format.

Scheduled for September 3, 2025, at the Merck office in Shanghai, this initiative offers an excellent opportunity for innovators to connect with industry leaders and gain valuable insights into the therapeutic landscape. We will be accepting applications from July to early August. To ensure a swift and efficient process, applications will be reviewed on a rolling basis, with invitations extended to pitch and present.

We encourage all innovators passionate about advancing healthcare to apply and seize this opportunity to make a significant impact in the field. Join us in our mission to foster innovation and collaboration in the healthcare sector!

What we're looking for

Innovators are invited to submit their novel assets, modalities and technologies that demonstrate superior safety and efficacy in Cardiovascular Disease, Metabolic Disease and Endocrinology, Fertility, Neurology, and Oncology with focus on Solid Tumors. Proposals focused on AI and machine learning to enhance drug discovery and development are also welcome.

We seek tangible innovations across all stages of development—from ideation and prototyping to piloting and commercial launches. Submissions must align with Merck's strategic priorities in our focus areas and demonstrate a clear path to commercialization. While early-stage ideas are encouraged, proposals should be grounded in practical, scalable solutions rather than purely academic research.

Please note that no monetary award will be offered for this challenge. Instead, this presents a valuable opportunity to showcase your innovation to Merck Healthcare leaders, to receive their insightful feedback and to network with leading industry peers.

Specific novel modalities and technologies include

• Next generation Antibody-Drug Conjugates

• Cell Engagers

• Nucleic acid therapies, such as small interference RNA (siRNA) Therapies and circular RNA

• Oral Peptides or proteins

• Treatment of male/female infertility, endometriosis, PCOS, ovarian insufficiency, novel delivery route of sex hormone, and AI to improve patient journey

• Platforms to identify novel antigens or to generate differentiated tumor-specific binders

Criteria

Potential applications will be assessed by a panel of reviewers based on their ability to meet the following criteria:

• Level of innovativeness of the asset, modality or technology

  The opportunity should be highly innovative and differentiated to Standard of Care and in-development assets in terms of efficacy, safety, route of administration, and other factors, offering significantly better clinical benefit to patients. The innovativeness must be supported with solid data, ideally clinical results.

• Strategic alignment or relevance to Merck's focused therapeutic areas

  The submitted opportunity should be relevant to Merck's search scope (see Appendix A), which includes Cardiovascular Disease, Metabolic Disease and Endocrinology (CM&E), Neurology, and Oncology, with focus on Solid Tumors.

• Validation level and/or proof of concept

  For CM&E and Fertility, clinical proof-of-concept (POC) is preferred, and assets in Phase 3 or later stages will be prioritized. For Neurology and Oncology, we are open to considering assets at all stages, with a strong clinical POC being a plus. For technology platforms, validation through use cases in the clinical stage is preferred. Please note that a high level of innovativeness is always required.

• Comprehensiveness of pitch deck

  We expect the elements listed in Appendix B to be included in the proposal. A business-friendly PowerPoint format is required. The description can be brief at the proposal submission stage to accommodate non-confidential requirements, but it should be sufficient for reviewers to identify the key highlights.

• Quality and capabilities of the team

  Please highlight the team's capabilities, particularly those of key individuals who provide the company with unique strengths

Please submit the pitch deck containing non-confidential information along with any supporting documents to the following address:grace.xiao@merckgroup.com

Appendix A: Merck Search Scope

Appendix B: Key Elements in Pitch Deck

Company profile:History, business focus, location, size, financial health, and management team.

Technology and pipeline:Scientific rationale and applications of the core technology platform, along with a snapshot of the pipeline that includes program code, mechanism of action (MoA), indication, development stage, and rights holder/collaborator.

Asset profile

· Disease background, including epidemiology data, current SoC, unmet needs, and market potential

· Mechanism of action (MoA) and target rationale

· Differentiation strategy with supporting data

· Target product profile (TPP), especially for late-stage assets

· Competition landscape: A concise comparison to SoC and emerging players, including MoA, route of administration (RoA), patient segment, treatment regimen, and non-clinical and clinical efficacy and safety data

· Clinical development plan and roadmap towards registration, including completed/ongoing/planned trials, along with regulatory milestones, presented in a detailed list and a Gantt chart to show the timeline

· Representative results including study design, data, and conclusion, with citations for data sources for cross-trial comparison.

· Outcome of communications with health authority (HA)

· CMC and material supply, especially for late-stage assets and advanced technology areas

· IP information, including any upstream obligations

· Collaboration potential and strategic fit between both sides

· referred collaboration model and expectations, such as investment in future clinical trials and retained rights.

· Contact information

默克是一家全球領(lǐng)先的科技公司，專注于生命科學(xué)、醫(yī)藥健康和電子科技三大領(lǐng)域。全球有超62,000名員工服務(wù)于默克，通過創(chuàng)造更加愉悅和可持續(xù)性的生活方式，為數(shù)百萬人的生活帶來積極的影響。2024年，默克在65個國家/地區(qū)的總銷售額達212億歐元。

科學(xué)探索和負責(zé)任的企業(yè)精神一直是默克科技進步的關(guān)鍵，也是默克自1668年以來永葆活力的秘訣。默克家族作為公司的創(chuàng)始者至今仍持有默克大部分的股份，我們在全球都叫“默克”，僅美國和加拿大例外。默克的三大領(lǐng)域：醫(yī)藥健康、生命科學(xué)及電子科技在這兩個國家分別稱之為“EMD Serono”、“MilliporeSigma”和“EMD Electronics”。默克在中國已經(jīng)有90余年發(fā)展歷史，目前擁有近4,500名員工，在北京、上海、無錫、蘇州、南通、香港等地擁有21家注冊公司。